BioNTech stock gains on fresh lung cancer data

Published on 09/18/2026 at 12:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech stock climbed 2.2 percent to USD 98.86 on September 17, 2026. UBS, Berenberg and Jefferies all kept Buy ratings with targets up to USD 140.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE stock (ISIN US09075V1026) closed at USD 98.86 on the Nasdaq on September 17, 2026, after a 2.2 percent gain. The move followed fresh lung cancer data that sent several brokers back to the table.

Analysts stay constructive

According to MSN on September 17, 2026, UBS analyst David Dai kept Buy on BioNTech and set a USD 135 target, while Berenberg's Harry Gillis and Jefferies' Akash Tewari also stayed at Buy with targets of USD 140 and USD 138.

The same MSN piece said the consensus across 14 covering houses stands at Strong Buy, with 11 Buy ratings and 3 Hold ratings, and a median target of USD 126.85.

Lung cancer data drive the focus

According to MSN on September 17, 2026, new study data showed a clear survival advantage in lung cancer, and pivotal testing is already under way at multiple sites worldwide.

That backdrop matters because the stock had already been trading with a wide analyst range of USD 96 to USD 140, which leaves room for a sharp reassessment if the data hold up.

Price still leads

BioNTech stock finished at USD 98.86 on Nasdaq on September 17, 2026, with the 52-week range cited in the market coverage stretching from USD 68.35 to USD 105.80. The share was 23 percent above its 52-week low and about 6.5 percent below the 52-week high.